Evidence map›Paper›PMID 35465470›Full record

ArticleClinical Medicine Insights. Oncology2022

Clinicopathological Features of Papillary Renal Cell Carcinoma With Venous Tumor Thrombus: Case Series from a Large Chinese Center.

Zhuo Liu, Liyuan Ge, Xun Zhao, Min Lu, Abudureyimujiang Aili, Yuxuan Li, Guodong Zhu, Peng Hong, Xiaojun Tian, Shumin Wang and 5 more

Open access · goldAbstract read
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. [Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Zhuo LiuDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Liyuan GeDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Xun ZhaoDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Min LuDepartment of Pathology, School of Basic Medical Sciences, Peking University Third Hospital, Peking University Health Science Center, Beijing, P.R. China.
Abudureyimujiang AiliDepartment of Radiation Oncology, Peking University Third Hospital, Beijing, P.R. China.
Yuxuan LiDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Guodong ZhuDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Peng HongDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Xiaojun TianDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Shumin WangDepartment of Ultrasound, Peking University Third Hospital, Beijing, P.R. China.
Hongxian ZhangDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Cheng LiuDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Zhenshan DingDepartment of Urology, China-Japan Friendship Hospital, Beijing, P.R. China.
Shudong ZhangDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.
Lulin MaDepartment of Urology, Peking University Third Hospital, Beijing, P.R. China.ORCID https://orcid.org/0000-0003-2141-9348
Peking University · CNChina-Japan Friendship Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Few studies have reported the influence of the histological classification of type-2 papillary renal cell carcinoma (PRCC), which may differ from that of clear cell renal carcinoma (ccRCC), on the prognosis of renal cell carcinoma with tumor thrombus. We investigated the clinicopathological features and prognosis of type-2 PRCC associated with venous tumor thrombi (PRCC-TT). Methods: We retrospectively analyzed 163 patients with renal cell carcinoma with venous tumor thrombus (RCC-TT) admitted to Peking University Third Hospital between June 2016 and June 2020. Twenty-five patients had type-2 PRCC-TT and 138 had ccRCC combined with tumor thrombus; there were 125 males and 38 females. All the included patients underwent radical nephrectomy and thrombectomy under either complete laparoscopic surgery or open surgery. Univariate and multivariate Cox regression analysis were performed to evaluate the prognostic significance of each variable on cancer-specific survival (CSS). Cancer-specific survival was calculated from the date of surgery to death or the last follow-up using the Kaplan-Meier method. Results: The blood vessels of type-2 PRCC-TT presented on CT images were not as abundant as those of ccRCC-TT. Slight enhancement was observed in the corticomedullary phase. While wash-out symptoms were observed, contrast agent extinction was not obvious in the nephrographic and excretory phases. We compared the macroscopic and microscopic appearances of the 2 cohorts. Compared to the ccRCC-TT cohort, lymph node invasion was more prevalent in the PRCC-TT cohort (88.0% vs. 60.9%, Conclusion: Type-2 PRCC-TT varies with common ccRCC-TT in imaging manifestation and pathological characteristics. The prognosis of type-2 PRCC-TT patients was worse than that of ccRCC-TT patients.

Indexed as

clear cell renal cell carcinomaClinicopathological featuresinferior vena cavapapillary renal cell carcinomatumor thrombus

Identifiers

PMID35465470
PMCPMC9019393
OpenAlexW4225583272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.